Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis.

CMUR > College of Health Care > Department of Respiratory Therapy > Journal articles > Item 310903500/55442

Please use this identifier to cite or link to this item: http://ir.cmu.edu.tw/ir/handle/310903500/55442

Title:	Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis.
Authors:	(K. Kubota);(Y. Ichinose);(G. Scagliotti);(D. Spigel);(J. H. Kim);(T. Shinkai);(K. Takeda);(S.-W. Kim);夏德椿(Te-Chun Hsia);(R. K. Li);(B. J. Tiangco);(S. Yau);(W.-T. Lim);(B. Yao);(Y.-J. Hei);(K. Park)*
Contributors:	健康照護學院二年制呼吸治療學系;中國附醫重症醫學中心
Keywords:	Asia, carboplatin, motesanib, NSCLC, paclitaxel
Date:	2014-01
Issue Date:	2015-12-30 09:03:21 (UTC+8)
Relation:	ANNALS OF ONCOLOGY 25(2):529-536
Appears in Collections:	[Department of Respiratory Therapy] Journal articles

Files in This Item:

File	Description	Size	Format
AA-EK00_20150608153023.docx		9Kb	Microsoft Word	91	View/Open
index.html		0Kb	HTML	115	View/Open